Table 2 Overall response rate, 2nd progression-free survival and 2nd overall survival according to second-line treatments.

From: Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO

Patients receiving second-line treatment, N = 419

 

FOLFOXIRI ± bev, N = 176

Doublets ± bev, N = 123

HR/OR (95% CI)a

P valuea

Other treatments, N = 120

HR/OR (95% CI)b

P valueb

P valuec

ORR (%)

23

11

2.29 (1.18–4.42)

0.012

15

1.67 (0.90–3.08)

0.10

0.031

2nd PFS (months)

6.1

4.4

0.76 (0.60–0.97)

0.029

3.9

0.71 (0.56–0.91)

0.007

0.013

2nd OS (months)

13.7

12.9

1.00 (0.76–1.31)

1.00

10

0.86 (0.65–1.14)

0.29

0.558

  1. 2nd PFS progression-free survival during second line, 2nd OS overall survival during second line, Bev bevacizumab, CI confidence interval, HR hazard ratio, ORR overall response rate, N number, OR odds ratio, bold indicates statistical significance (p-value < 0.05).
  2. aFOLFOXIRI ± bev versus doublets ± bev.
  3. bFOLFOXIRI ± bev versus other treatments.
  4. cFOLFOXIRI ± bev versus doublets ± bev versus other treatments.
Back to article page